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Primary mucoepidermoid tumors of the lung are rare entities. Synchronous primary malignancies of the lung involving
mucoepidermoid carcinoma and mucinous adenocarcinoma are even rarer and constitute a unique set of patient population. The
presentation, diagnosis and treatment strategies for this patient population are not well described. In most cases, the diagnosis of
synchronous primary lungmalignancy ismade after pathological examination of the resected lung specimen.Molecular and genetic
analysis is now being used to supplement the diagnosis of synchronous primary lung malignancies. In this work, we briefly discuss
the current state of knowledge of this unique combination of primary lung malignancies and describe the clinical presentation and
management of a patient with a rare combination of synchronous primary lung malignancies.
1. Introduction
Synchronous tumors are defined as two or more primary
neoplasms which are detected simultaneously. They differ
from metachronous tumors which are detected after an
intervening interval in their epidemiology, prognosis, and
management [1]. Precancerous lesions have been found at
a higher frequency in patients with multiple primary lung
cancers, but the genetic basis of such malignancies is yet
to be elucidated [2, 3]. It is possible that the development
of synchronous tumors is related more to environmental
exposure than to genetic predisposition as seen by the higher
incidence of synchronous tumors in workers exposed to
chromate [4]. However, there is some evidence to show that
genetic predisposition may play a role as multiple primary
lung cancers have been observed to be inherited in some
families [5]. Mutations in the p53 protein and allelic loss
of heterozygosity have been shown to be associated with
synchronous lung primary malignancies [6, 7]. Similar trend
with malignancies involving other organ systems has been
noted in patients with significant smoking history providing
credence to the hypothesis of field cancerization [8].
The diagnosis of true synchronous primary lung tumors
with different histologies has been difficult due to two
reasons: some patients with multiple primary lung tumors
with different histologies have been found to have identical
genetic changes suggesting a monoclonal origin and some
with patients with identical histologies have been found to
have different clonal origins [9–11]. This is complicated by
the fact that regional heterogeneity in tumor grade can be
observed in individual neoplasms and metastases may have
different tumor grades when compared to their primary
lesions [12]. Notably, imaging with fludeoxyglucose-positron
emission tomography (FDG-PET) has been noted to have
differences in uptake between different lesions in patients
with synchronous primary lung tumors [13]. However, the
clinical significance of this finding is not yet clear and has not
factored into treatment strategies. It is also possible that the
second primary malignancy may represent a metastasis from
an extrapulmonary site, and hence a thorough evaluation
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for other primaries is warranted [14]. Recent studies have
shown microsatellite analysis to be useful in differentiating
the multiple primary tumors from each other and also from
metastases [15].
Mucoepidermoid carcinoma is a common salivary gland
tumor which is often seen in the digestive system and the
respiratory tract.They were first described in 1945 by Stewart
et al. [16] in the salivary glands and in the tracheobronchial
tree by Smetana et al. [17]. Metastasis to the skeletal muscle,
pericardium, pleura, mediastinum, central nervous system,
gastrointestinal tract, and kidney has been described [18–21].
Primary pulmonary mucoepidermoid carcinomas are rare
and comprise 0.1-0.2% of primary lung malignancies [22].
Synchronousmucoepidermoid andmucinous adenocarcino-
mas are even rarer and there are very few reports in medical
literature which describe this combined entity.
2. Case Description
The patient is a 68-year-old lady with a past medical history
significant for hypertension, hyperlipidemia, and hypothy-
roidism who presented with complaints of lower abdominal
pain, diarrhea, and bright red blood per rectum. She was a
retired medical assistant who had quit smoking 3-4 weeks
prior to presentation after having smoked half pack a day
for 30 years. Her home medications included lisinopril,
simvastatin, aspirin, levothyroxine, and calcium and vitamin
D supplementation. Her review of systems was positive for
mild intermittent dry cough for the past 1.5 months. She
denied fever, chills, weight loss, productive cough, hemop-
tysis, night sweats, and changes in urinary habits. She had
unlimited exercise tolerance. Her physical examination in the
emergency department was unremarkable except for mild
tenderness to palpation over the lower abdomen.A computed
tomography (CT) scan of the abdomen showed sigmoid and
distal ascending colon colitis and incidentally identified a
right hilar mass. The mass was in the superior segment of
the right lower lobe and extended throughout the lower lobe
along the pulmonary vessels (Figure 1). The central part of
the mass was enhancing with hypodensity noted peripherally
suggestive of necrosis. The dominant portion of the mass
measured up to 6 cm transverse × 3.4 cm antero-posterior.
The tracheobronchial tree was found to be patent. An addi-
tional irregular, pleural based mass in the superior segment
of the right lower lobe was also identified which measured
3.9 cm transverse × 1.5 cm anteroposterior. An additional
pleural nodularity was noted in the inferior portion of the
right lower lobe. These findings were highly suggestive of
a right lower lobe malignancy. There was no significant
mediastinal, axillary, or hilar adenopathy noted except for a
subcarinal (9mm in short axis) and paratracheal lymph node
(5mm in short axis). She underwent bronchoscopy which
showed a friable exophytic endobronchial mass in the right
lower lobe at 1 cm from the bronchus intermedius, rest of
the anatomy normal. Bronchial brushings and endobronchial
biopsies × 3 were done. Immunostaining was positive for
mucicarmine, cytokeratin 7 (CK7), p63, focally positive
for cytokeratins 5,6 (CK 5,6), negative for synaptophysin,
Figure 1: Transverse section on a chest CT demonstrating the
presence of tumor lesions in the right middle and lower lobes.
thyroid transcription factor-1 (TTF-1), epidermal growth
factor receptor (EGFR), anaplastic lymphoma kinase (ALK)
and Napsin A (hematoxylin and eosin stains are shown in
Figures 2(a), 2(b), 2(c) and 2(d); immunostaining in Figures
3(a), 3(b), 3(c), and 3(d)). Positron emission tomography-
CT (PET-CT) showed a large focus of intense uptake in the
lower right lung medially, corresponding to a hilar mass
extending to the lower lobe seen on chest CT. No other
focal abnormalities are noted. She underwent right sided
Video-Assisted Thoracic Surgery (VATS) with right middle
and lower lobe bilobectomy with lymph node dissection.
Pathology showed 2 separate synchronous carcinomas (1st
tumor: nonsmall cell carcinoma, favor mucoepidermoid;
2nd tumor: mucinous adenocarcinoma). It was deemed that
the patient had 2 distinct primaries, both staged at T2N1.
Patient refused chemotherapy and has been doing well after
procedure.
3. Discussion
Patients with synchronous lung tumors have been shown
to have a worse prognosis when compared with patients
with lung malignancy at a similar stage [23, 24]. In the
past, pneumonectomy was associated with poor outcomes in
patients with multiple synchronous primary tumors, but this
trend has changed recently with aggressive surgical treatment
[25–27].This change has been attributed to a relative increase
in patient population with tumors at an earlier stage, possibly
linked to better detection techniques and increased surveil-
lance. While tumor size and lung function have been shown
to be independent predictors of survival, female gender seems
to be prognosticator for better outcomes [1]. Patients with
metachronous tumors on the other hand have been shown
to have a better survival rate when compared to patients with
synchronous lung primary malignancies [28, 29].
More than 50% of mucoepidermoid carcinomas have
a characteristic translocation between chromosomes 11q
and 19p [30, 31]. This rearrangement results in the forma-
tion of a fusion protein between mucoepidermoid carci-
noma translocated-1 (MECT1) and mastermind-like protein
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Figure 2: (a) Hematoxylin and eosin (H & E) stain showing endobronchial invasion of mucoepidermoid carcinoma. (b) H & E staining
showing the mucinous component of mucoepidermoid carcinoma. (c) H & E staining showing the solid component of mucoepidermoid
carcinoma. (d) H & E staining of mucinous adenocarcinoma.
2 (MAML2) genes [32]. MECT1 protein activates the c-
AMP response element-binding mediated transcription and
MAML-2 protein is a part of notch signaling [33, 34]. The
formation of this fusion protein has been shown to be
pathognomic for most of mucoepidermoid carcinomas [34,
35]. It was initially thought that presence of the fusion protein
was associated with better median survival, but recently it
has been shown that these patients did not have significant
disease-free survival despite better disease-specific survival
[30, 36]. The role of the fusion protein as a prognosticator
remains controversial [37, 38].
Surgical resection has been the mainstay of treatment
for low grade mucoepidermoid carcinomas but neodymium
yttrium aluminum garnet (Nd-YAG) laser has also been
used [39, 40]. Adjuvant chemotherapy has been reserved
for unresectable and advanced cases with limited success.
The mortality of high grade mucoepidermoid carcinomas
continues to remain high [41]. In rare caseswhere the tumor is
limited to the same lobe, surgical resection has been curative
for synchronous lesions involving bothmucoepidermoid and
adenocarcinoma [42].
4. Conclusion
The patient described here underwent surgery with an
excellent outcome. This case report serves to illustrate the
rarity of synchronous lung malignancies involving mucoepi-
dermoid carcinoma and mucinous adenocarcinoma. It also
demonstrates that early surgical intervention in patients with
synchronous lung malignancies at early stages may have
favorable outcomes despite the involvement ofmore than one
lung lobe.
Disclosure
The study has not been presented in any form in any meeting
or forum. All authors have read the paper and agree to the
content.
4 Case Reports in Oncological Medicine
(a) (b)
(c) (d)
Figure 3: Immunohistochemistry showing staining with mucicarmine (a), CK 5, and 6 (b), p63 (c) and CK 7 (d).
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